Glycomine
PrivateLast Round
Series C
Apr 16, 2025
Total Funding Raised
$228M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Glycomine is a biopharmaceutical company that develops orphan drugs aimed at treating rare metabolic disorders and protein misfolding through innovative replacement therapies and targeted intracellular delivery systems.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Glycomine Comparables
Compare Glycomine with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Applied Therapeutics Inc | 78% | |
| Maggie's Pearl, LLC | 77% | |
| Sentynl Therapeutics | 76% |
Glycomine Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series C | Apr 16, 2025 | ||||
| Series B | Jun 23, 2021 | ||||
| Series B | Aug 7, 2019 | ||||
| Series A | Nov 16, 2016 |
Glycomine Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Aberdeen Group plc | Series C |
| Asahi Kasei Therapeutics Venture Capital | Series B |
| Mesa Verde Venture Partners | Series A |
| CTI Life Sciences Fund | Series C |
| abrdn Inc. | Series C |
| Remiges Ventures | Series C, Series B |
| Advent Life Sciences | Series C |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 18, 2026
Monthly visitors grew 63% MoM, from 1.3K to 2.2K.
- Apr 16, 2025
$115M round raised
Glycomine Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Glycomine's valuation, stock price, and market status.
Is Glycomine a public or private company?
Glycomine is a private company.
What is the current stock price of Glycomine?
Glycomine is a private company with no public stock price. No recent secondary market data is available.
How much is Glycomine worth (valuation)?
Valuation information for Glycomine is not publicly available.
Can I buy Glycomine stock?
Glycomine shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Glycomine's last funding round?
Glycomine's most recent funding round was Series C on April 16, 2025.
Who are the main investors in Glycomine?
Key investors in Glycomine include CTI Life Sciences Fund, abrdn Inc., Advent Life Sciences, Abingworth, Novo Holdings.
Will Glycomine IPO soon?
No public IPO plans have been announced for Glycomine.
How can I track Glycomine secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Glycomine's secondary market activity and sign up for updates.